Alps Group

Alps Group Financial Leverage

The Financial Leverage (Equity Multiplier) of Alps Group (ALPS) as of Oct 20, 2026 is -0.50. In the previous year, Financial Leverage (Equity Multiplier) was 1.40 — a change of -135.50% (lower).

Financial Leverage

-0.50

YoY

-135.50%

Last updated:

Financial Leverage (Equity Multiplier) of Alps Group is 2024 -0.50 . Financial Leverage (Equity Multiplier) of Alps Group was 2023 1.40 . It decreases by -135.50% lower compared to the previous year.

The Alps Group Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2022
1.04 USD
Jan 1, 2023
1.40 USD
Jan 1, 2024
-0.50 USD
The Alps Group Financial Leverage history
YEARFinancial LeverageYoY
-0.50-135.50%
1.40+33.90%
1.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alps Group Stock analysis

What does Alps Group do? Alps Group Inc generates revenue through its integrated biotechnology platform Alps Life Sciences Inc., which offers advanced therapies and healthcare solutions. The company provides medical services, wellness solutions, and aesthetic treatments including non-surgical and surgical aesthetic services. Alps Life Sciences Inc. develops and commercializes therapies such as MyImmune (NK cells), CAR-T cells, and diabetes therapeutics, alongside research in mRNA vaccine technology and stem cell advancements like iPSCs. The firm operates molecular and cGMP laboratories for research and cultivation of cell and gene therapies. Alps Group Inc. targets global healthcare providers and patients seeking advanced medical solutions. Its biotechnology pipeline covers diverse areas including cancer therapies, infectious disease treatments, and regenerative medicine. The company's integrated ecosystem combines research, development, medical services, and wellness solutions to improve healthcare outcomes. The firm's aesthetic services cater to individuals seeking cosmetic and wellness procedures, while its medical services address broader healthcare needs. The company's revenue streams include the sale of medical services, wellness solutions, and aesthetic treatments. Alps Life Sciences Inc. focuses on developing therapies for specific health conditions such as diabetes and cancer, with a pipeline that includes mRNA-based vaccines and cell therapies. The molecular and cGMP laboratories support the development and production of these advanced therapies, contributing to the company's product offerings. Alps Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alps Group stock

Financial Leverage (Equity Multiplier) of Alps Group is -0.50 in 2024.

Financial Leverage (Equity Multiplier) of Alps Group changed from 1.40 to -0.50, representing a -135.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Alps Group since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Alps Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Alps Group

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Alps Group